Drugs in the Pipeline, News
Tofacitinib Ext-Rel Monotherapy Effective for Moderate to Severe RA After Methotrexate Withdrawal
The ORAL Shift study enrolled 694 RA patients who were inadequate responders to methotrexate alone.
Your search for tofacitinib returned 10 results
Safety Alerts and Recalls
Boxed Warning Added to Tofacitinib Prescribing Information
The Food and Drug Administration (FDA) has approved changes to the prescribing information for tofacitinib to include new warnings, including a Boxed Warning, regarding an increased risk of blood clots and death associated with the 10mg twice daily regimen. The update comes after a review of data from an ongoing safety clinical trial of tofacitinib…
AIBD 2019
Impact of Tofacitinib on Extraintestinal Symptoms in UC Patients Examined
Treatment with tofacitinib appears to have little impact on extraintestinal manifestations (EIMs) in patients with moderate to severe ulcerative colitis (UC) and might even improve them, according to an analysis of the OCTAVE program. Findings were presented at the 2019 AIBD Annual Meeting in Orlando, Florida.
AIBD 2019
Tofacitinib vs Vedolizumab: Short-Term Efficacy Compared in Ulcerative Colitis
In patients with ulcerative colitis (UC), tofacitinib, a Janus kinase inhibitor, was associated with improved short-term efficacy, when compared with vedolizumab, an integrin receptor antagonist. Findings were presented at the Advances in Inflammatory Bowel Disease (AIBD) 2019 meeting in Orlando, Florida.
Safety Alerts and Recalls
Increased Risk of Pulmonary Embolism, Death in RA Patients Reported in Tofacitinib Postmarketing Study
According to data from on an ongoing postmarketing safety trial conducted by Pfizer, tofacitinib dosed at 10mg twice daily was associated with an increased risk of pulmonary embolism and overall mortality in patients with rheumatoid arthritis (RA).
News
Xeljanz XR Approved for Ulcerative Colitis
The FDA has approved Xeljanz XR (tofacitinib extended-release; Pfizer) for the treatment of adult patients with moderately to severely active ulcerative colitis.
Drugs in the Pipeline
Upadacitinib Gets FDA’s Priority Review for Treatment of Moderate to Severe RA
The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for upadacitinib (AbbVie), an investigational oral JAK1-selective inhibitor, for the treatment of moderate to severe rheumatoid arthritis (RA).
AIBD 2019
Timing of Biologic/JAK Inhibitor Treatment Initiation in IBD Patients Examined
According to new research over 1 in 5 patients with inflammatory bowel disease (IBD) should have started treatment with an advanced systemic therapy earlier in their disease.
AIBD 2019
Worsening Symptoms, Heart Failure in UC Patient Treated With Mesalamine
The patient had been diagnosed with mild-to-moderate ulcerative colitis (UC) a month prior to presentation for which she was prescribed oral mesalamine.
News
Drug Repurposing Study Shows PDE5 Inhibitors Do Not Reduce Dementia Risk
By identifying existing medications that may be repurposed for dementia, clinicians may be able to provide faster treatment for those in need.
